Metastasis, Breast Cancer
Conditions
Keywords
Breast Cancer Brain Metastases (BCBM), Carcinoma
Brief summary
This is an open-label, randomized, active comparator, multicenter, international Phase 3 study of NKTR-102 versus TPC in patients with metastatic breast cancer who have stable brain metastases and have been previously treated with an anthracycline, a taxane, and capecitabine in either the adjuvant or metastatic setting (prior anthracycline may be omitted if medically appropriate or contraindicated for the patient).
Detailed description
This is an open-label, randomized, active comparator, multicenter, international Phase 3 study of NKTR-102 versus TPC in patients with metastatic breast cancer who have stable brain metastases and have been previously treated with an anthracycline, a taxane, and capecitabine in either the adjuvant or metastatic setting (prior anthracycline may be omitted if medically appropriate or contraindicated for the patient). In Group A, NKTR-102 will be administered at a dose level of 145 mg/m2 on a q21d schedule as a 90-minute intravenous (IV) infusion on Day 1 of each treatment cycle. In Group B, TPC will be administered per standard of care. Patients randomized to TPC will receive single-agent IV chemotherapy, limited to choice of one of the following 7 agents: eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel. This study will randomize approximately 220 patients using a 1:1 randomization ratio and stratification based on geographic region, tumor receptor status, and Eastern Cooperative Oncology Group (ECOG) status. At Screening, the Investigator must determine which TPC will be offered to the patient. Data will be collected on subsequent anticancer therapies in both treatment groups from the time patients come off the study treatment until the time of primary data analysis for Overall Survival (OS). An independent data monitoring committee (DMC) will assess interim safety and efficacy data and determine final number of death events needed to provide 80% conditional power based on the zone adaptive design.
Interventions
DRUGNKTR-102
DRUGEribulin
DRUGIxabepilone
DRUGVinorelbine
DRUGGemcitabine
DRUGPaclitaxel
DRUGDocetaxel
DRUGNab-paclitaxel
Sponsors
Nektar Therapeutics
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Female or male, age ≥ 18 years. * Histologically-confirmed carcinoma of the breast (either the primary or metastatic lesions) for whom single-agent cytotoxic chemotherapy is indicated. Patients may have either measurable or non-measurable disease according to RECIST version 1.1. * Patients must have a history of brain metastases that are non-progressing. * For triple-negative breast cancer, a minimum of 1 prior cytotoxic chemotherapy regimen must have been administered for the indication of metastatic disease.Depending on receptor status, 1 or 2 prior cytotoxic regimens are required prior to enrollment in this trial; hormonal and/or human epidermal growth factor receptor 2 (HER2) -targeted agents may be required. * Have had prior therapy (administered in the neoadjuvant, adjuvant, and/or metastatic setting) with an anthracycline, a taxane, and capecitabine (prior anthracycline can be omitted if not medically appropriate or contraindicated for the patient). * Last dose of anticancer therapy must have been administered within 6 months of the date of randomization into this study. * All anticancer- and radiation therapy-related toxicities must be completely resolved or downgraded to Grade 1 or less (neuropathy may be Grade 2 or less). * Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Demonstrate adequate organ function obtained within 14 days prior to randomization and analyzed by the central laboratory. * Women of childbearing potential (WCBP) must agree to use highly effective methods of birth control throughout the duration of the study until 6 months following the last dose of study drug. * Males with female partners of child-bearing potential must agree to use a barrier contraception (e.g., condom with spermicidal foam/gel/film/cream/suppository) throughout the duration of the study until 6 months following the last dose of study drug; in addition to their female partner using either an intrauterine device or hormonal contraception and continuing until 6 months following the last dose of study drug. Male patients should not donate sperm until 6 months following the last dose of study drug.
Exclusion criteria
* Last dose of anticancer therapy (including HER2-targeted therapy) within 14 days prior to randomization. * High-dose chemotherapy followed by stem cell transplantation (autologous or allogeneic). * Major surgery within 28 days prior to randomization. * Concomitant use of any anticancer therapy or use of any investigational agent(s). * Received prior treatment for cancer with a camptothecin-derived agent. * Lesions on imaging, by cerebrospinal fluid or with neurological findings that are consistent with leptomeningeal disease or meningeal carcinomatosis. * Chronic or acute GI disorders resulting in diarrhea of any severity grade. * Patients who are pregnant or lactating, plan to get pregnant, or have a positive serum pregnancy test prior to randomization. * Enzyme-inducing anti-epileptic drugs (EIAEDs) within 14 days of randomization. * Hepatitis B or C, tuberculosis, or HIV. * Cirrhosis. * Prior malignancy (other than breast cancer) unless diagnosed and definitively treated more than 5 years prior to randomization. * Daily use of oxygen supplementation. * Significant known cardiovascular impairment. * Prior treatment with NKTR-102. * Psychiatric illness, social situation, or geographical situation that preclude informed consent or limit compliance. * Known intolerance or hypersensitivity to any of the products used in this study or their excipients. * For patients selecting vinorelbine or gemcitabine as the TPC agent, patients may not receive yellow fever vaccine in the 28 days prior to randomization.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) of Patients | Within 3 years from study start | To compare Overall Survival (OS) of patients who receive 145 mg/m2 NKTR-102 given once every 21 days (q21d) with OS of patients who receive Treatment of Physician's Choice (TPC). Overall survival is defined as the time from the date of randomization to the date of death from any cause. Patients will be followed until their date of death or until final database closure. Patients who are lost-to-follow-up or are alive at the time of analysis will be censored at the time they were last known to be alive or at the date of event cut-off for OS analysis. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-Free Survival in Brain Metastasis (PFS-BM) | Through study completion, an expected average of 1 year | Progression-Free Survival in Brain Metastasis (PFS-BM) is defined as the time from the date of randomization to the earliest evidence of documented Progressive Disease (PD) per Response Assessment in Neuro-Oncology-Brain Metastases (RANO-BM) in brain metastases or death from any cause. The PD will also be determined by the investigator's assessments. Progressive Disease (PD) is defined as at least a 20% increase in the sum of longest diameters of CNS target lesions, taking as reference the smallest sum on study. This included the baseline sum if that was the smallest on study. In addition to the relative increase of 20%, at least 1 lesion had to increase by an absolute value of 5 mm or more to be considered progression. |
| Progression-Free Survival (Overall) | Through study completion, an expected average of 1 year | Progression-free survival (CNS and peripheral) is defined as the time from the date of randomization to the earliest evidence of documented PD in either the CNS or peripheral (using RANO-BM) or death from any cause. The PD will be determined by both the investigator's and the central imaging facility assessments. The same statistical methods that were used for PFS and PFS-BM will be used for PFS (Overall). Progressive Disease (PD) is defined as at least a 20% increase in the sum of longest diameters of CNS target lesions, taking as reference the smallest sum on study. This included the baseline sum if that was the smallest on study. In addition to the relative increase of 20%, at least 1 lesion had to increase by an absolute value of 5 mm or more to be considered progression. |
| Objective Response Rates (ORR) of the NKTR-102 Treatment and the Treatment of Physician's Choice (TPC) | Through study completion, an expected average of 1 year | RECIST criteria for lesions outside the Central Nervous System (CNS); RANO-BM criteria for CNS lesions) based upon the best response as assessed by the central imaging facility. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had to have reduction in short axis to \< 10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. ORR is calculated as the sum of CR and PR. Progressive Disease (PD) is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that was the smallest on study). Stable Disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. |
| Clinical Benefit Rate (CBR) | For at least 4 months, with an expected average of 1 year | Clinical Benefit Rate will be defined as the proportion of patients having a Complete Response (CR), Partial Response (PR), or Stable Disease (SD) for at least 4 months (≥ 120 days). CR is defined as disappearance of all target lesions for at least 4 weeks with no new lesions, not use of corticosteroids, and patient was stable or improved clinically. PR is defined as at least a 30% decrease in the sum of longest diameters sustained for at least 4 weeks, no new lesions; stable to decreased corticosteroid dose; stable or improved clinically. Progressive Disease (PD) is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that was the smallest on study). Stable Disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. |
| Duration of Response (DoR) | Through study completion, an expected average of 1 year | Duration of response (DoR) outside the CNS will be defined as the time from first documented CR or PR until the earliest evidence of disease progression per RECIST v1.1 or death from any cause. CR is defined as disappearance of all target lesions for at least 4 weeks with no new lesions, not use of corticosteroids, and patient was stable or improved clinically. PR is defined as at least a 30% decrease in the sum of longest diameters sustained for at least 4 weeks, no new lesions; stable to decreased corticosteroid dose; stable or improved clinically. Progressive Disease (PD) is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that was the smallest on study). Stable Disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. |
| Progression-Free Survival (Outside the Central Nervous System) | Through study completion, an expected average of 1 year | Progression-Free Survival (PFS) is defined as the time from the date of randomization to the earliest evidence of documented Progressive Disease (PD) or of death from any cause. The date of global deterioration or symptomatic deterioration will not be used as the date of PD. The assessment of PFS outside the CNS will utilize RECIST criteria v1.1. |
| Compare Health-Related Quality of Life (HRQoL) Using the the EuroQoL 5D (EQ-5D-5L™) | Baseline (prior to first dose of study treatment in Cycle 1 [cycle length = 21 for NKTR-102 or 28 days for TPC] and end of Cycle 44 | The EQ-5D-5L scale is used to measure health by having a patient answer a series of questions. There are a series of 5 questions each of which is scaled from a score of 4-20 in increasing increments of 4. The scale is numbered from 0 to 100 where 100 means the beast health you can imagine and 0 means the worst health. |
| Compare Health-Related Quality of Life (HRQoL) Using the Brief Fatigue Inventory (BFI) | Baseline (prior to first dose of study treatment in Cycle 1 [cycle length = 21 for NKTR-102 or 28 days for TPC] and end of Cycle 44 | The Brief Fatigue Inventory scale utilizes a series of 4 questions. The first three are scored with a scale from 1-10. The fourth question has 6 six sub components each of which are scored with a scale of 1-10. For every scale, a score of 0 indicates no fatigue/interference where a score of 10 indicates as bad as you can imagine. A patient's score can range from 0 to 100 where 0 indicates the best outcome and 100 indicates the worst. |
| Magnitude of Clinical Benefit Assessed by ESMO-MCBS Derived From Overall Survival | Through study completion, within 3 years from study start | The magnitude of clinical benefit of NKTR-102 is assessed by the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) (v1.0). The scale is graded 5, 4, 3, 2, 1, where grades 5 and 4 represent a high level of proven clinical benefit, and grade 1 represents no clinical benefit. To determine the magnitude of clinical benefit when the median OS with the standard of treatment is ≤ 1 year, the score is derived from the Hazard Ratio (HR) of Overall Survival, overall survival gain, and QoL improvement between two treatment arms. Values reported in the data table are Overall Survival values. |
| Number of Participants With Adverse Events as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.3 | Through study completion, an expected average of 1 year | The number of participants with adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.3 |
| Compare Health-Related Quality of Life (HRQoL) Using the European Organisation for Treatment of Cancer (EORTC) Quality of Life Core 30 (QLQ-C30) Module With the Brain Neoplasms 20-question (BN-20) Subscale. | Baseline (prior to first dose of study treatment in Cycle 1 [cycle length = 21 for NKTR-102 or 28 days for TPC] and end of Cycle 44. | The EORTC QLQ-BN20 Scale has a series of 20 questions each of which involve reporting a scale from 1-4. It is an increasing scale where a score of one indicates not at all while a score of four indicates very much. The minimum score is 20 and the maximum score is 80. The higher the score the worse the outcome. |
Countries
Australia, Belgium, Canada, France, Israel, Italy, Portugal, Spain, United Kingdom, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| NKTR-102 NKTR-102 will be administered at a dose level of 145 mg/m2 on a q21d schedule as a 90-minute intravenous (IV) infusion on Day 1 of each treatment cycle. | 92 |
| Treatment of Physician's Choice (TPC) TPC will be administered per standard of care. Patients randomized to TPC will receive single-agent IV chemotherapy, limited to choice of one of the following 7 agents: eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel. | 86 |
| Total | 178 |
Baseline characteristics
| Characteristic | NKTR-102 | Treatment of Physician's Choice (TPC) | Total |
|---|---|---|---|
| Age, Continuous | 54.7 years STANDARD_DEVIATION 10.13 | 51.9 years STANDARD_DEVIATION 10.5 | 53.3 years STANDARD_DEVIATION 10.37 |
| Breast Cancer at Initial Diagnosis I | 5 Participants | 10 Participants | 15 Participants |
| Breast Cancer at Initial Diagnosis II | 41 Participants | 29 Participants | 70 Participants |
| Breast Cancer at Initial Diagnosis III | 22 Participants | 17 Participants | 39 Participants |
| Breast Cancer at Initial Diagnosis IV | 10 Participants | 16 Participants | 26 Participants |
| Breast Cancer at Initial Diagnosis Unknown | 14 Participants | 14 Participants | 28 Participants |
| Cancer Histology at Initial Diagnosis Invasive Ductal Carcinoma | 80 Participants | 77 Participants | 157 Participants |
| Cancer Histology at Initial Diagnosis Invasive Lobular Carcinoma | 6 Participants | 1 Participants | 7 Participants |
| Cancer Histology at Initial Diagnosis Other | 6 Participants | 8 Participants | 14 Participants |
| Eastern Cooperative Oncology Group (ECOG) 0 | 25 Participants | 25 Participants | 50 Participants |
| Eastern Cooperative Oncology Group (ECOG) 1 | 67 Participants | 61 Participants | 128 Participants |
| Estrogen Receptor/Progesterone Receptor Status at Last Biopsy ER/PgR Negative | 36 Participants | 35 Participants | 71 Participants |
| Estrogen Receptor/Progesterone Receptor Status at Last Biopsy ER/PgR Positive | 49 Participants | 49 Participants | 98 Participants |
| Estrogen Receptor/Progesterone Receptor Status at Last Biopsy Unknown | 7 Participants | 2 Participants | 9 Participants |
| Estrogen Receptor Status at Initial Diagnosis ER Negative | 40 Participants | 34 Participants | 74 Participants |
| Estrogen Receptor Status at Initial Diagnosis ER Positive | 52 Participants | 49 Participants | 101 Participants |
| Estrogen Receptor Status at Initial Diagnosis Unknown | 0 Participants | 3 Participants | 3 Participants |
| Estrogen Receptor Status at Last Biopsy ER Negative | 38 Participants | 36 Participants | 74 Participants |
| Estrogen Receptor Status at Last Biopsy ER Positive | 47 Participants | 48 Participants | 95 Participants |
| Estrogen Receptor Status at Last Biopsy Unknown | 7 Participants | 2 Participants | 9 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 2 Participants | 6 Participants | 8 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 69 Participants | 60 Participants | 129 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 21 Participants | 20 Participants | 41 Participants |
| Height | 162.7 centimeters STANDARD_DEVIATION 6.67 | 162.1 centimeters STANDARD_DEVIATION 7.73 | 162.4 centimeters STANDARD_DEVIATION 7.19 |
| HER2 Receptor Status at Last Biopsy HER2 Negative | 74 Participants | 69 Participants | 143 Participants |
| HER2 Receptor Status at Last Biopsy HER2 Positive | 12 Participants | 13 Participants | 25 Participants |
| HER2 Receptor Status at Last Biopsy Unknown | 6 Participants | 4 Participants | 10 Participants |
| Human Epidermal Growth Factor Receptor (HER2) Status at Initial Diagnosis HER2 Negative | 76 Participants | 66 Participants | 142 Participants |
| Human Epidermal Growth Factor Receptor (HER2) Status at Initial Diagnosis HER2 Positive | 15 Participants | 14 Participants | 29 Participants |
| Human Epidermal Growth Factor Receptor (HER2) Status at Initial Diagnosis Unknown | 1 Participants | 6 Participants | 7 Participants |
| Pregnancy Test at Screening Borderline | 6 Participants | 1 Participants | 7 Participants |
| Pregnancy Test at Screening Negative | 22 Participants | 24 Participants | 46 Participants |
| Pregnancy Test at Screening Not Performed | 63 Participants | 60 Participants | 123 Participants |
| Pregnancy Test at Screening Performed | 29 Participants | 26 Participants | 55 Participants |
| Pregnancy Test at Screening Positive | 1 Participants | 1 Participants | 2 Participants |
| Progesterone Receptor (PgR) Status at Initial Diagnosis PgR Negative | 50 Participants | 41 Participants | 91 Participants |
| Progesterone Receptor (PgR) Status at Initial Diagnosis PgR Positive | 40 Participants | 42 Participants | 82 Participants |
| Progesterone Receptor (PgR) Status at Initial Diagnosis Unknown | 2 Participants | 3 Participants | 5 Participants |
| Progesterone Receptor Status at Last Biopsy PgR Negative | 51 Participants | 52 Participants | 103 Participants |
| Progesterone Receptor Status at Last Biopsy PgR Positive | 32 Participants | 31 Participants | 63 Participants |
| Progesterone Receptor Status at Last Biopsy Unknown | 9 Participants | 3 Participants | 12 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 3 Participants | 6 Participants | 9 Participants |
| Race (NIH/OMB) Black or African American | 3 Participants | 5 Participants | 8 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 20 Participants | 18 Participants | 38 Participants |
| Race (NIH/OMB) White | 66 Participants | 57 Participants | 123 Participants |
| Reproductive Status Missing | 0 Participants | 0 Participants | 0 Participants |
| Reproductive Status Of Child-Bearing Potential | 16 Participants | 13 Participants | 29 Participants |
| Reproductive Status Other | 0 Participants | 4 Participants | 4 Participants |
| Reproductive Status Post-Menopausal | 65 Participants | 55 Participants | 120 Participants |
| Reproductive Status Surgically Sterile | 11 Participants | 14 Participants | 25 Participants |
| Sex: Female, Male Female | 92 Participants | 86 Participants | 178 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants |
| Time since Initial Brain Metastasis Diagnosis | 1.137 years STANDARD_DEVIATION 1.1061 | 1.194 years STANDARD_DEVIATION 1.1748 | 1.165 years STANDARD_DEVIATION 1.1369 |
| Time since Initial Breast Cancer Diagnosis | 8.094 years STANDARD_DEVIATION 5.17 | 6.950 years STANDARD_DEVIATION 5.0941 | 7.541 years STANDARD_DEVIATION 5.151 |
| Weight | 67.16 kilograms STANDARD_DEVIATION 17.468 | 65.97 kilograms STANDARD_DEVIATION 15.561 | 66.59 kilograms STANDARD_DEVIATION 16.539 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 2 / 90 | 0 / 77 |
| other Total, other adverse events | 90 / 90 | 76 / 77 |
| serious Total, serious adverse events | 33 / 90 | 24 / 77 |
Outcome results
Primary
Overall Survival (OS) of Patients
To compare Overall Survival (OS) of patients who receive 145 mg/m2 NKTR-102 given once every 21 days (q21d) with OS of patients who receive Treatment of Physician's Choice (TPC). Overall survival is defined as the time from the date of randomization to the date of death from any cause. Patients will be followed until their date of death or until final database closure. Patients who are lost-to-follow-up or are alive at the time of analysis will be censored at the time they were last known to be alive or at the date of event cut-off for OS analysis.
Time frame: Within 3 years from study start
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| NKTR-102 | Overall Survival (OS) of Patients | 7.8 months |
| Treatment of Physician's Choice (TPC) | Overall Survival (OS) of Patients | 7.5 months |
Secondary
Clinical Benefit Rate (CBR)
Clinical Benefit Rate will be defined as the proportion of patients having a Complete Response (CR), Partial Response (PR), or Stable Disease (SD) for at least 4 months (≥ 120 days). CR is defined as disappearance of all target lesions for at least 4 weeks with no new lesions, not use of corticosteroids, and patient was stable or improved clinically. PR is defined as at least a 30% decrease in the sum of longest diameters sustained for at least 4 weeks, no new lesions; stable to decreased corticosteroid dose; stable or improved clinically. Progressive Disease (PD) is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that was the smallest on study). Stable Disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
Time frame: For at least 4 months, with an expected average of 1 year
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| NKTR-102 | Clinical Benefit Rate (CBR) | # of Patients who achieved Complete Response | 0 participants |
| NKTR-102 | Clinical Benefit Rate (CBR) | # of Patients who achieved Clinical Benefit Rate (CBR) | 23 participants |
| NKTR-102 | Clinical Benefit Rate (CBR) | # of Patients who achieved Partial Response | 6 participants |
| NKTR-102 | Clinical Benefit Rate (CBR) | # of Patients who have Stable Disease >= 120 days | 17 participants |
| Treatment of Physician's Choice (TPC) | Clinical Benefit Rate (CBR) | # of Patients who have Stable Disease >= 120 days | 5 participants |
| Treatment of Physician's Choice (TPC) | Clinical Benefit Rate (CBR) | # of Patients who achieved Clinical Benefit Rate (CBR) | 11 participants |
| Treatment of Physician's Choice (TPC) | Clinical Benefit Rate (CBR) | # of Patients who achieved Partial Response | 6 participants |
| Treatment of Physician's Choice (TPC) | Clinical Benefit Rate (CBR) | # of Patients who achieved Complete Response | 0 participants |
Secondary
Compare Health-Related Quality of Life (HRQoL) Using the Brief Fatigue Inventory (BFI)
The Brief Fatigue Inventory scale utilizes a series of 4 questions. The first three are scored with a scale from 1-10. The fourth question has 6 six sub components each of which are scored with a scale of 1-10. For every scale, a score of 0 indicates no fatigue/interference where a score of 10 indicates as bad as you can imagine. A patient's score can range from 0 to 100 where 0 indicates the best outcome and 100 indicates the worst.
Time frame: Baseline (prior to first dose of study treatment in Cycle 1 [cycle length = 21 for NKTR-102 or 28 days for TPC] and end of Cycle 44
Population: As the trial progressed, some patients discontinued study treatment as a result of progressive disease, non-PD AE, patient decision, or physician decision.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| NKTR-102 | Compare Health-Related Quality of Life (HRQoL) Using the Brief Fatigue Inventory (BFI) | BFI Score at Baseline | 4.18 Units on a Scale | Standard Deviation 2.264 |
| NKTR-102 | Compare Health-Related Quality of Life (HRQoL) Using the Brief Fatigue Inventory (BFI) | BFI Score at End of Treatment, approximately 1 year | 4.83 Units on a Scale | Standard Deviation 2.476 |
| Treatment of Physician's Choice (TPC) | Compare Health-Related Quality of Life (HRQoL) Using the Brief Fatigue Inventory (BFI) | BFI Score at Baseline | 4.04 Units on a Scale | Standard Deviation 2.401 |
| Treatment of Physician's Choice (TPC) | Compare Health-Related Quality of Life (HRQoL) Using the Brief Fatigue Inventory (BFI) | BFI Score at End of Treatment, approximately 1 year | 4.74 Units on a Scale | Standard Deviation 2.373 |
Secondary
Compare Health-Related Quality of Life (HRQoL) Using the European Organisation for Treatment of Cancer (EORTC) Quality of Life Core 30 (QLQ-C30) Module With the Brain Neoplasms 20-question (BN-20) Subscale.
The EORTC QLQ-BN20 Scale has a series of 20 questions each of which involve reporting a scale from 1-4. It is an increasing scale where a score of one indicates not at all while a score of four indicates very much. The minimum score is 20 and the maximum score is 80. The higher the score the worse the outcome.
Time frame: Baseline (prior to first dose of study treatment in Cycle 1 [cycle length = 21 for NKTR-102 or 28 days for TPC] and end of Cycle 44.
Population: As the trial progressed, some patients discontinued study treatment as a result of progressive disease, non-PD AE, patient decision, or physician decision.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| NKTR-102 | Compare Health-Related Quality of Life (HRQoL) Using the European Organisation for Treatment of Cancer (EORTC) Quality of Life Core 30 (QLQ-C30) Module With the Brain Neoplasms 20-question (BN-20) Subscale. | QLQ-C30 Score at Baseline | 57.59 Units on a Scale | Standard Deviation 21.607 |
| NKTR-102 | Compare Health-Related Quality of Life (HRQoL) Using the European Organisation for Treatment of Cancer (EORTC) Quality of Life Core 30 (QLQ-C30) Module With the Brain Neoplasms 20-question (BN-20) Subscale. | QLQ-C30 Score at End of Treatment, approximately 1 year | 46.97 Units on a Scale | Standard Deviation 24.582 |
| Treatment of Physician's Choice (TPC) | Compare Health-Related Quality of Life (HRQoL) Using the European Organisation for Treatment of Cancer (EORTC) Quality of Life Core 30 (QLQ-C30) Module With the Brain Neoplasms 20-question (BN-20) Subscale. | QLQ-C30 Score at Baseline | 52.25 Units on a Scale | Standard Deviation 24.236 |
| Treatment of Physician's Choice (TPC) | Compare Health-Related Quality of Life (HRQoL) Using the European Organisation for Treatment of Cancer (EORTC) Quality of Life Core 30 (QLQ-C30) Module With the Brain Neoplasms 20-question (BN-20) Subscale. | QLQ-C30 Score at End of Treatment, approximately 1 year | 52.38 Units on a Scale | Standard Deviation 24.801 |
Secondary
Compare Health-Related Quality of Life (HRQoL) Using the the EuroQoL 5D (EQ-5D-5L™)
The EQ-5D-5L scale is used to measure health by having a patient answer a series of questions. There are a series of 5 questions each of which is scaled from a score of 4-20 in increasing increments of 4. The scale is numbered from 0 to 100 where 100 means the beast health you can imagine and 0 means the worst health.
Time frame: Baseline (prior to first dose of study treatment in Cycle 1 [cycle length = 21 for NKTR-102 or 28 days for TPC] and end of Cycle 44
Population: As the trial progressed, some patients discontinued study treatment as a result of progressive disease, non-PD AE, patient decision, or physician decision.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| NKTR-102 | Compare Health-Related Quality of Life (HRQoL) Using the the EuroQoL 5D (EQ-5D-5L™) | EQ-5D-5L Score at Baseline | 61.41 Units on a Scale | Standard Deviation 19.739 |
| NKTR-102 | Compare Health-Related Quality of Life (HRQoL) Using the the EuroQoL 5D (EQ-5D-5L™) | EQ-5D-5L Score at End of Treatment, approximately 1 year | 56.53 Units on a Scale | Standard Deviation 23.467 |
| Treatment of Physician's Choice (TPC) | Compare Health-Related Quality of Life (HRQoL) Using the the EuroQoL 5D (EQ-5D-5L™) | EQ-5D-5L Score at Baseline | 60.33 Units on a Scale | Standard Deviation 23.004 |
| Treatment of Physician's Choice (TPC) | Compare Health-Related Quality of Life (HRQoL) Using the the EuroQoL 5D (EQ-5D-5L™) | EQ-5D-5L Score at End of Treatment, approximately 1 year | 61.60 Units on a Scale | Standard Deviation 20.858 |
Secondary
Duration of Response (DoR)
Duration of response (DoR) outside the CNS will be defined as the time from first documented CR or PR until the earliest evidence of disease progression per RECIST v1.1 or death from any cause. CR is defined as disappearance of all target lesions for at least 4 weeks with no new lesions, not use of corticosteroids, and patient was stable or improved clinically. PR is defined as at least a 30% decrease in the sum of longest diameters sustained for at least 4 weeks, no new lesions; stable to decreased corticosteroid dose; stable or improved clinically. Progressive Disease (PD) is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that was the smallest on study). Stable Disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
Time frame: Through study completion, an expected average of 1 year
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| NKTR-102 | Duration of Response (DoR) | 7.4 months |
| Treatment of Physician's Choice (TPC) | Duration of Response (DoR) | 3.5 months |
Secondary
Magnitude of Clinical Benefit Assessed by ESMO-MCBS Derived From Overall Survival
The magnitude of clinical benefit of NKTR-102 is assessed by the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) (v1.0). The scale is graded 5, 4, 3, 2, 1, where grades 5 and 4 represent a high level of proven clinical benefit, and grade 1 represents no clinical benefit. To determine the magnitude of clinical benefit when the median OS with the standard of treatment is ≤ 1 year, the score is derived from the Hazard Ratio (HR) of Overall Survival, overall survival gain, and QoL improvement between two treatment arms. Values reported in the data table are Overall Survival values.
Time frame: Through study completion, within 3 years from study start
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| NKTR-102 | Magnitude of Clinical Benefit Assessed by ESMO-MCBS Derived From Overall Survival | 7.8 months |
| Treatment of Physician's Choice (TPC) | Magnitude of Clinical Benefit Assessed by ESMO-MCBS Derived From Overall Survival | 7.5 months |
Secondary
Number of Participants With Adverse Events as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.3
The number of participants with adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.3
Time frame: Through study completion, an expected average of 1 year
Population: 167 patients received at least one dose of study treatment and were included in the Safety population for this outcome.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| NKTR-102 | Number of Participants With Adverse Events as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.3 | 90 Participants |
| Treatment of Physician's Choice (TPC) | Number of Participants With Adverse Events as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.3 | 76 Participants |
Secondary
Objective Response Rates (ORR) of the NKTR-102 Treatment and the Treatment of Physician's Choice (TPC)
RECIST criteria for lesions outside the Central Nervous System (CNS); RANO-BM criteria for CNS lesions) based upon the best response as assessed by the central imaging facility. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had to have reduction in short axis to \< 10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. ORR is calculated as the sum of CR and PR. Progressive Disease (PD) is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that was the smallest on study). Stable Disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
Time frame: Through study completion, an expected average of 1 year
Population: 156 patients had measurable disease by RECIST v 1.1 at baseline and were included in the Response Evaluable population for this outcome.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| NKTR-102 | Objective Response Rates (ORR) of the NKTR-102 Treatment and the Treatment of Physician's Choice (TPC) | Stable Disease | 16 Participants |
| NKTR-102 | Objective Response Rates (ORR) of the NKTR-102 Treatment and the Treatment of Physician's Choice (TPC) | Not Evaluable | 18 Participants |
| NKTR-102 | Objective Response Rates (ORR) of the NKTR-102 Treatment and the Treatment of Physician's Choice (TPC) | Objective Response Rate (CR+PR) | 4 Participants |
| NKTR-102 | Objective Response Rates (ORR) of the NKTR-102 Treatment and the Treatment of Physician's Choice (TPC) | Missing | 7 Participants |
| NKTR-102 | Objective Response Rates (ORR) of the NKTR-102 Treatment and the Treatment of Physician's Choice (TPC) | Progressive Disease | 38 Participants |
| Treatment of Physician's Choice (TPC) | Objective Response Rates (ORR) of the NKTR-102 Treatment and the Treatment of Physician's Choice (TPC) | Missing | 4 Participants |
| Treatment of Physician's Choice (TPC) | Objective Response Rates (ORR) of the NKTR-102 Treatment and the Treatment of Physician's Choice (TPC) | Stable Disease | 5 Participants |
| Treatment of Physician's Choice (TPC) | Objective Response Rates (ORR) of the NKTR-102 Treatment and the Treatment of Physician's Choice (TPC) | Progressive Disease | 32 Participants |
| Treatment of Physician's Choice (TPC) | Objective Response Rates (ORR) of the NKTR-102 Treatment and the Treatment of Physician's Choice (TPC) | Not Evaluable | 30 Participants |
| Treatment of Physician's Choice (TPC) | Objective Response Rates (ORR) of the NKTR-102 Treatment and the Treatment of Physician's Choice (TPC) | Objective Response Rate (CR+PR) | 2 Participants |
Secondary
Progression-Free Survival in Brain Metastasis (PFS-BM)
Progression-Free Survival in Brain Metastasis (PFS-BM) is defined as the time from the date of randomization to the earliest evidence of documented Progressive Disease (PD) per Response Assessment in Neuro-Oncology-Brain Metastases (RANO-BM) in brain metastases or death from any cause. The PD will also be determined by the investigator's assessments. Progressive Disease (PD) is defined as at least a 20% increase in the sum of longest diameters of CNS target lesions, taking as reference the smallest sum on study. This included the baseline sum if that was the smallest on study. In addition to the relative increase of 20%, at least 1 lesion had to increase by an absolute value of 5 mm or more to be considered progression.
Time frame: Through study completion, an expected average of 1 year
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| NKTR-102 | Progression-Free Survival in Brain Metastasis (PFS-BM) | 3.9 months |
| Treatment of Physician's Choice (TPC) | Progression-Free Survival in Brain Metastasis (PFS-BM) | 3.3 months |
Secondary
Progression-Free Survival (Outside the Central Nervous System)
Progression-Free Survival (PFS) is defined as the time from the date of randomization to the earliest evidence of documented Progressive Disease (PD) or of death from any cause. The date of global deterioration or symptomatic deterioration will not be used as the date of PD. The assessment of PFS outside the CNS will utilize RECIST criteria v1.1.
Time frame: Through study completion, an expected average of 1 year
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| NKTR-102 | Progression-Free Survival (Outside the Central Nervous System) | 2.8 months |
| Treatment of Physician's Choice (TPC) | Progression-Free Survival (Outside the Central Nervous System) | 1.9 months |
Secondary
Progression-Free Survival (Overall)
Progression-free survival (CNS and peripheral) is defined as the time from the date of randomization to the earliest evidence of documented PD in either the CNS or peripheral (using RANO-BM) or death from any cause. The PD will be determined by both the investigator's and the central imaging facility assessments. The same statistical methods that were used for PFS and PFS-BM will be used for PFS (Overall). Progressive Disease (PD) is defined as at least a 20% increase in the sum of longest diameters of CNS target lesions, taking as reference the smallest sum on study. This included the baseline sum if that was the smallest on study. In addition to the relative increase of 20%, at least 1 lesion had to increase by an absolute value of 5 mm or more to be considered progression.
Time frame: Through study completion, an expected average of 1 year
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| NKTR-102 | Progression-Free Survival (Overall) | 2.1 months |
| Treatment of Physician's Choice (TPC) | Progression-Free Survival (Overall) | 1.9 months |